Latest News

Date Title Topic
04 Feb 2016 ESMO Supports World Cancer Day 2016 Bioethics, legal and economic issues
04 Feb 2016 EMA Adopts a New Indication for Lenalidomide Haematologic malignancies - Anticancer agents & Biologic therapy
03 Feb 2016 Reshaping the Cancer Clinic Personalised medicine
07 Apr 2016 ESMO Preceptorship on Immuno-Oncology 2016: Siena
02 Feb 2016 ESMO Press Release: Keith Hanson McGregor Appointed New ESMO CEO
02 Feb 2016 FDA Approves Eribulin Mesylate for the Treatment of Unresectable or Advanced Liposarcoma Sarcomas - Anticancer agents & Biologic therapy
01 Feb 2016 EMA Recommends Granting a Marketing Authorisation for Elotuzumab Haematologic malignancies - Anticancer agents & Biologic therapy
29 Jan 2016 Cancer in China Epidemiology/Etiology/Cancer Prevention
28 Jan 2016 FDA Extends Indications for Ofatumumab in CLL Haematologic malignancies - Anticancer agents & Biologic therapy
27 Jan 2016 Nivolumab plus Ipilimumab Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status Melanoma - Cancer Immunology and Immunotherapy
27 Jan 2016 Annals of Oncology Press Release: Important falls in death rates from leukaemia in Europe predicted for 2016 Haematologic malignancies
Cervical Cancer
22 Jan 2016 NEW for 2016! European Integration Fellowship
19 Jan 2016 ESMO Workshop: Cancer Patient Advocacy Networks Driving Research